𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease

✍ Scribed by H. Steed; G. T. Macfarlane; K. L. Blackett; B. Bahrami; N. Reynolds; S. V. Walsh; J. H. Cummings; S. Macfarlane

Book ID
108606039
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
456 KB
Volume
32
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Randomized, double-blind, placebo-contro
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients